Related Experiment Video

Updated: Jul 17, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

HER family inhibitors in pancreatic cancer: current status and future directions

David Berz1, Thomas Miner, Elise McCormack

  • 1The Brown University Oncology Group, 164 Summit Avenue, Providence, RI 02906, USA. hsafran@lifespan.org

Expert Opinion on Therapeutic Targets
|February 15, 2007
PubMed

Insights

Targeting the HER family of receptors in pancreatic cancer with new therapies, including tyrosine kinase inhibitors and monoclonal antibodies, shows promise for improving patient survival and future treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Pancreatic cancer exhibits numerous genetic alterations, presenting therapeutic targets.
  • The Human Epidermal growth factor Receptor (HER) family comprises four key transmembrane receptors involved in cell growth.
  • Targeting HER1 with erlotinib has shown survival benefits in advanced pancreatic cancer.

Purpose of the Study:

  • To review clinical trials of HER family inhibitors in pancreatic cancer.
  • To discuss the role of these agents in patient management.
  • To outline future directions for pancreatic cancer treatment.

Main Methods:

  • Review of clinical trials involving HER family inhibitors.
  • Analysis of therapeutic agents including tyrosine kinase inhibitors and monoclonal antibodies.
  • Examination of agents' potential as radiation sensitizers.

Main Results:

  • Erlotinib (targeting HER1) demonstrated a survival advantage in advanced pancreatic cancer.
  • Various HER family inhibitors (tyrosine kinase inhibitors, monoclonal antibodies) are under investigation.
  • These agents may also function as radiation sensitizers.

Conclusions:

  • HER family inhibitors represent a promising therapeutic avenue for pancreatic cancer.
  • Ongoing research and clinical trials are crucial for optimizing treatment strategies.
  • Targeted therapies offer potential for improved outcomes in pancreatic cancer management.

More Related Videos

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...